Articles related to EPILEPSY/SEIZURES

The NAUTILUS trial met its primary safety endpoint for responsive centromedian thalamic stimulation in drug-resistant idiopathic generalized epilepsy. The prespecified primary effectiveness endpoint was not significant, while post hoc and 18-month outcomes showed sustained seizure reductions.

A large Veterans Health Administration study found that older adults with traumatic brain injury had elevated rates of several neurologic disorders both before and after injury. The findings support a bidirectional association between TBI and neurologic disease but do not establish causality.

A joint epilepsy society position statement endorsed validated noninvasive seizure detection and alerting devices as part of individualized epilepsy care while emphasizing their strongest performance in tonic-clonic seizures and the absence of proven SUDEP prevention.

County-level analysis of nearly 5 million Medicare beneficiaries identified more than 10-fold geographic variation in late-onset epilepsy incidence, with insufficient sleep, heat index, and lack of vehicle access among the strongest area-level predictors.

Most newly diagnosed focal epilepsy patients required more than a year and more than one antiseizure medication to reach seizure freedom in a multicenter cohort.

Late-breaking sessions at AAN 2026 spanned rare disease, migraine prevention, epilepsy, FTD, MS, early Alzheimer’s, neuropathic pain, and stiff person syndrome, with mixed signals across disease-modifying and symptomatic therapies.